The short answer
St. John’s wort should not be combined with Biktarvy. Current prescribing guidance warns that it may lower bictegravir and tenofovir alafenamide levels, potentially weakening HIV treatment. Taking the herb and medicine a few hours apart is not an established solution.
What this answer covers
Adult oral Biktarvy with Hypericum perforatum, commonly called St. John’s wort. The fixed combination contains bictegravir, emtricitabine and tenofovir alafenamide; induction concerns are not treated as a measured effect on every component.
- Supplement or preparation
- Hypericum perforatum
- Medication ingredient
- bictegravir
Why is this combination discouraged?
St. John’s wort can increase the activity of drug-metabolizing enzymes and transporters. Biktarvy labeling warns that this may lower bictegravir and tenofovir alafenamide exposure. Too little antiretroviral medicine can compromise viral suppression and contribute to resistance. The U.S. label says coadministration is not recommended, and NIH guidance says not to coadminister them. These are precautionary treatment instructions rather than a measured failure rate for this exact pair.
Why does separating doses not solve it?
This concern involves changes in enzyme and transporter activity, not simply two products binding while they are together in the stomach. A morning-evening schedule therefore does not establish protection. Unlike certain mineral interactions with bictegravir, no hourly separation plan is recommended for St. John’s wort. Ask your prescriber or HIV pharmacist to review alternatives rather than trying to manage the combination with timing alone.
Does every herbal preparation have the same effect?
St. John’s wort preparations can differ in the constituents responsible for induction. That variability prevents assigning one numerical effect to every extract, tea or mixed product. It also does not establish that a product is suitable with Biktarvy just because its label describes it as mild or natural. Check for the botanical name Hypericum perforatum on mood and sleep supplements as well as products labeled St. John’s wort.
What if I am already taking both?
Tell your HIV care team promptly and bring the supplement label, dose and start date. Continue your prescribed HIV treatment while they assess the combination and arrange an appropriate plan; do not skip Biktarvy or raise its dose yourself. If St. John’s wort is being used for mood symptoms, discuss an alternative treatment plan as well. Follow-up may include a review of other medicines and viral suppression.
Evidence and practical considerations
Absorption & effectiveness
St. John’s wort should not be combined with Biktarvy. Current prescribing guidance warns that it may lower bictegravir and tenofovir alafenamide levels, potentially weakening HIV treatment. Taking the herb and medicine a few hours apart is not an established solution.
- Exact scope
- Adult oral Biktarvy with Hypericum perforatum, commonly called St. John’s wort. The fixed combination contains bictegravir, emtricitabine and tenofovir alafenamide; induction concerns are not treated as a measured effect on every component. with Adult oral bictegravir as Biktarvy 50/200/25 mg fixed combination
- Medication form and route
- Adult oral bictegravir as Biktarvy 50/200/25 mg fixed combination; oral botanical product within stated preparation scope
- Timing or duration
- Current guidance addresses ongoing coadministration and enzyme/transporter induction. An exact-pair clinical trial or universal time to onset/offset was not identified.
What remains uncertain
- Avoidance is established guidance, but the exact bictegravir exposure reduction and clinical failure probability are not measured in a retrieved pair-specific trial. Herbal composition varies and no safe hourly spacing rule is established.
Factors that may matter: Exact botanical species, plant part, extract composition and daily amount; Recent initiation, duration or discontinuation of the botanical; Biktarvy fixed-combination components and concurrent medicines; Adherence and viral suppression.
Read the supporting source summaries
Source 1: current U.S. regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People using the fixed combination Biktarvy for HIV treatment; adult-strength tablets contain bictegravir 50 mg, emtricitabine 200 mg and tenofovir alafenamide 25 mg.
Give Biktarvy at least 2 hours before or 6 hours after aluminum/magnesium antacids. Calcium or iron can be taken together with food; routine simultaneous fasting administration or Biktarvy 2 hours after calcium/iron is not recommended. St. John’s wort coadministration is not recommended because bictegravir and tenofovir alafenamide may decrease.
How this applies: Exact bictegravir active ingredient is bridged from bictegravir sodium by the label’s declared equivalent dose. Cation findings concern bictegravir; St. John’s wort can also affect the tenofovir alafenamide component. No emtricitabine interaction is inferred. Exact article scope: Adult oral Biktarvy with Hypericum perforatum, commonly called St. John’s wort. The fixed combination contains bictegravir, emtricitabine and tenofovir alafenamide; induction concerns are not treated as a measured effect on every component.
Combination-product labeling, not evidence for bictegravir monotherapy. Named antacid directions are not direct experiments on every nutritional magnesium/aluminum formulation. The label supplies no echinacea trial or measured interaction for every multivitamin. Pregnancy has explicit additional fasting instructions.
Source 2: U.S. expert clinical treatment guideline
clinicalinfo.hiv.gov · Source check Sep 10, 2026
Population: Adults and adolescents receiving integrase inhibitor regimens for HIV.
Bictegravir mineral directions depend on cation and food. If raltegravir must be used with polyvalent mineral supplements, give it at least 2 hours before or 6 hours after and monitor virologic response. Multivitamin chelation magnitude is uncertain. Raltegravir antacid rules are separate: avoid Al/Mg, and distinguish calcium carbonate 400 mg twice daily from 1,200 mg once daily. Do not coadminister bictegravir with St. John’s wort.
How this applies: Exact-drug management guidance. Bictegravir sodium and raltegravir potassium are interpreted through their labels’ active-moiety equivalents. Calcium/iron food exceptions for bictegravir do not transfer to raltegravir. Exact article scope: Adult oral Biktarvy with Hypericum perforatum, commonly called St. John’s wort. The fixed combination contains bictegravir, emtricitabine and tenofovir alafenamide; induction concerns are not treated as a measured effect on every component.
Expert recommendations include predicted interactions where exact-pair clinical studies are absent. A suggested supplement schedule does not supersede the distinct antacid avoidance instructions. No universal safe dose or virologic risk percentage is established.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Current exact-drug labeling and guidance checked; original human studies and neutral findings assessed. Current statements adjudicated with formulation, food and directional timing corrections. Article written; clinical sign-off not recorded. | |
| Research summary published |
Article revision: 0d4943b5134f179c
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.